Medicamen Biotech

Medicamen Biotech FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Medicamen Biotech (MEDICAMEQ.NS) as of Oct 19, 2026 is -411.86 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -167.86 % — a change of 145.36% (lower).

FCF Conversion

-411.86 %

YoY

145.36%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Medicamen Biotech is 2026 -411.86 % . FCF Conversion Rate (FCF/EBITDA) of Medicamen Biotech was 2025 -167.86 % . It decreases by 145.36% lower compared to the previous year.

The Medicamen Biotech FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
-94.63 INR
Jan 1, 2020
-186.66 INR
Jan 1, 2021
-42.82 INR
Jan 1, 2022
-30.20 INR
Jan 1, 2023
-86.86 INR
Jan 1, 2024
-119.21 INR
Jan 1, 2025
-167.86 INR
Jan 1, 2026
-411.86 INR
The Medicamen Biotech FCF Conversion history
YEARFCF ConversionYoY
-411.86 %+145.36%
-167.86 %+40.81%
-119.21 %+37.24%
-86.86 %+187.62%
-30.20 %-29.48%
-42.82 %-77.06%
-186.66 %+97.24%
-94.63 %-29.84%
-134.88 %-646.96%
24.66 %-97.86%
1,150.37 %-250.46%
-764.58 %-117.31%
4,415.85 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Medicamen Biotech Stock analysis

What does Medicamen Biotech do? Medicamen Biotech Ltd, based in New Delhi, India, operates in the Health Care sector, specifically within Pharmaceuticals. The company manufactures and markets diverse pharmaceutical formulations, including oral solids, liquids, ointments, and injectables for both non-oncology and oncology treatments. It focuses on oncology therapeutics, cardiology, central nervous system disorders, diabetology, and pain management. With 388 employees, Medicamen Biotech produces a range of products such as tablets, capsules, syrups, and specialized oncology drugs like Abiraterone acetate and Imatinib mesylate. Medicamen Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medicamen Biotech stock

FCF Conversion Rate (FCF/EBITDA) of Medicamen Biotech is -411.86 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Medicamen Biotech changed from -167.86 % to -411.86 %, representing a 145.36% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Medicamen Biotech since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Medicamen Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Medicamen Biotech

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Medicamen Biotech